样式: 排序: IF: - GO 导出 标记为已读
-
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-03-05 Paolo Dapavo, Martina Burlando, Claudio Guarneri, Matteo Megna, Alessandra Narcisi, Marina Talamonti, Paolo Gisondi
The introduction of biologics for the treatment of plaque psoriasis is one of the major therapeutic advances of the last decades in dermatology. The efficacy of this class of drugs can be influence...
-
Emerging anti-spike monoclonal antibodies against SARS-CoV-2 Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-03-03 Eloy E. Ordaya, Raymund R. Razonable
Anti-spike monoclonal antibodies (mAbs) were previously authorized for the prevention and treatment of COVID-19 in immunocompromised patients. However, they are no longer authorized in the US due t...
-
The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-03-04 Hong De Sa, Richard T. Maziarz, Arpita P. Gandhi
The success of an allogeneic hematopoietic stem cell transplantation (alloHCT) is measured by cure from the underlying malignancy, immune reconstitution (IR), and freedom from graft-versus-host dis...
-
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-29 Gabriele Roccuzzo, Eleonora Gherardi, Michele Maio, Piergiorgio Malagoli, Angelo Valerio Marzano, Aurora Parodi, Nicola Pimpinelli, Francesco Spagnolo, Anna Maria Di Giacomo, Pietro Quaglino
Immunomodulating therapies harness the power of the immune system to combat disease. In advanced melanoma, immune checkpoint inhibitors have significantly improved survival outcomes by activating t...
-
More failure with solanezumab – this time in preclinical Alzheimer’s disease Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-27 Sheila A Doggrell
There is no cure for Alzheimer’s disease, which is the sixth leading cause of death in the U.S.A.. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer’s disease b...
-
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-26 Anan S. Jarab, Shrouq R Abu Heshmeh, Ahmad Z. Al Meslamani
Published in Expert Opinion on Biological Therapy (Just accepted, 2024)
-
Targeting cervical cancer with anti-PD-1 antibodies: what’s new? Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-23 Michelle Greenman, Blair McNamara, Levent Mutlu, Alessandro D Santin
Published in Expert Opinion on Biological Therapy (Just accepted, 2024)
-
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-22 Lukas Pekar, Simon Krah, Stefan Zielonka
Published in Expert Opinion on Biological Therapy (Just accepted, 2024)
-
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-20 Na-Qiong Wu, Zhi-Fan Li, Meng-Ying Lu, Jian-Jun Li
Dyslipidemia significantly contributes to atherosclerotic cardiovascular disease (ASCVD). Patients with lipid-rich vulnerable plaques are particularly susceptible to cardiovascular complications. D...
-
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-13 Anhye Kim, Jang Hee Hong, Wonsuk Shin, Hyounggyoon Yoo, Jin-Gyu Jung, Jean-Yves Reginster, SungHyun Kim, YunJu Bae, JeeHye Suh, Sera Kim, EunKyung Lee, Stuart Silverman
This study’s objective was to demonstrate pharmacokinetic (PK) similarity and safety of denosumab biosimilar, CT‑P41, and United States – licensed reference denosumab (US-denosumab) in healthy male...
-
Epcoritamab in B-cell malignancies: current status and prospects Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-11 Stefano Molica, Marco Rossi, David Allsup
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 1-2, 2024)
-
Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-06 Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, Alfredo Papa
The therapeutic armamentarium for managing Crohn’s disease (CD) has expanded significantly in recent decades. Several biologics with three different mechanisms of action [anti-tumor necrosis factor...
-
Streamlining biosimilar development based on 20 years’ experience Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-05 Cecil Nick
Biosimilar clinical programs could be streamlined by prudent application of improved methodologies and knowledge accumulated over the past twenty years. This review focuses on whether complex compa...
-
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-07 Julia Lang-Meli, Christoph Neumann-Haefelin, Robert Thimme
More than 350 million people worldwide live with chronic viral hepatitis and are thus at risk for severe complications like liver cirrhosis and hepatocellular carcinoma (HCC). To meet the goals of ...
-
The latest advances in the use of biological DMARDs to treat Still’s disease Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-04 Ilenia Di Cola, Piero Ruscitti
Currently, the therapeutic management of Still’s disease, a multisystemic inflammatory rare disorder, is directed to target the inflammatory symptoms and signs of patients. The treatment varies fro...
-
Clinical advances in biological therapy for generalized pustular psoriasis: a review Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-04 Chang-Yu Hsieh, Tsen-Fang Tsai
In 2022, U.S. Food and Drug Administration (FDA) approved the first biologics, intravenous spesolimab, for acute flare of generalized pustular psoriasis (GPP). The drug works by blocking IL-36 sign...
-
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-02-02 Kamila Polgarova, Marek Trneny
Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains poor. Novel strategies...
-
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-31 Alexander K. Tsai, Sana Kagalwalla, Jenna Langer, Thuy Le-Kumar, Vikas Le-Kumar, Emmanuel S. Antonarakis
Immunotherapies have revolutionized the management of various malignancies but have only recently been evaluated systematically in prostate cancer. Pembrolizumab, a programmed-death 1 (PD-1) blocki...
-
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-30 Marco Caminati, Claudio Micheletto, Francesca Norelli, Bianca Olivieri, Giancarlo Ottaviano, Roberto Padoan, Giorgio Piacentini, Michele Schiappoli, Gianenrico Senna, Francesco Menzella
Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, effectively blocks both IL-4 and IL-13 mediated pathways. Its introduction has represented a significant advancement in t...
-
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-26 Barbara Vogg, Johann Poetzl, Rachid El Galta, Rainard Fuhr, Arnd Schwebig, Susmit Sekhar
This Phase I study compared the pharmacokinetic (PK) and pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference denosumab (a monoclonal antibody for specific pro-resor...
-
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-25 Antonio Tursi, Giammarco Mocci, Franco Scaldaferri, Daniele Napolitano, Rossella Maresca, Daniela Pugliese, Gianluca Semprucci, Edoardo Savarino, Antonio Cuomo, Laura Donnarumma, Giorgia Bodini, Andrea Pasta, Giovanni Maconi, Giovanni Cataletti, Giuseppe Pranzo, Stefano Rodinò, Ladislava Sebkova, Francesco Costa, Antonio Ferronato, Federica Gaiani, Manuela Marzo, Ileana Luppino, Giulia Fabiano, Pietro
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effect...
-
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-21 Dina V. Hingorani
Antibody drug conjugates (ADCs) have emerged as a potent tool in cancer treatment, where cytotoxic drugs are linked to antibodies targeting specific antigens. While conventional ADC synthesis metho...
-
Short and long-term economic implications of biosimilars Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-17 Ahmad Z. Al Meslamani
Biosimilars are gaining popularity due to their ability to offer comparable therapeutic benefits at potentially lower costs.This article analyses studies that compare the cost savings of biosimilar...
-
Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2024-01-05 Ahmad Z Al Meslamani
Asthma is a global health problem, with alarming prevalence and mortality rates. Biologic therapies, particularly monoclonal antibodies such as omalizumab, have emerged as promising alternatives, t...
-
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 A Chiricozzi, SM Ferrucci, L Di Nardo, N Gori, A Balato, M Ortoncelli, M Maurelli, M Galluzzo, M Munera Campos, T Seremet, G Caldarola, C De Simone, E Ippoliti, T Torres, S Gkalpakiotis, C Conrad, JM Carrascosa, L Bianchi, G Argenziano, S Ribero, G Girolomoni, AV Marzano, K Peris, MEDaCoTRA Study Group
Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinum...
-
Intravenous immunoglobulin as a potential treatment for long COVID Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Matthew W. McCarthy
On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Hea...
-
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Alexandria Matic, Nouf Alfaidi, Vera Bril
Myasthenia gravis (MG) is an auto-immune disease characterized by fluctuating symptoms of muscle weakness and fatigue. Corticosteroids and corticosteroid-sparing broad-spectrum immunosuppression pl...
-
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Massimo Martino, Filippo Antonio Canale, Gaetana Porto, Chiara Verduci, Giovanna Utano, Giorgia Policastro, Jessyca Germanò, Caterina Alati, Ludovica Santoro, Lucrezia Imbalzano, Martina Pitea
Chimeric Antigen Receptor ;(CAR) T cells therapies have become part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The weakness of CAR-T ...
-
Adjuvant immunotherapy for locally advanced renal cell carcinoma Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Michail Alevizakos, David McDermott
Locally advanced renal cell carcinoma (RCC) presents a therapeutic challenge due to 20–40% relapse risk post-nephrectomy. There has been substantial interest in utilizing immunotherapy interrupting...
-
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Hendrik Wessels, Oliver von Richter, Maria Velinova, Josef Höfler, Paul Chamberlain, Arno Kromminga, Dirk Lehnick, Karsten Roth
PB006 (Polpharma Biologics S.A; marketed as Tyruko®, Sandoz) is an approved biosimilar to natalizumab (Tysabri®; Biogen [ref-NTZ]). This multicenter, double-blind, randomized, single-dose study was...
-
Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Nik Kamperidis, Moulesh Shah, Sophie Young, Evgeniy Galimov, Shruti Sweeney, Naila Arebi
Data on the optimum positioning of biologics in the treatment of inflammatory bowel disease (IBD) are limited.This was a longitudinal retrospective study of linked health-care data from northwest L...
-
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Damian García-Olmo, Mariano Garcia-Arranz
This study provides an overview of the development of the first drug authorized for use in cell therapy.We analyze the case of darvadstrocel, an example of a successful cell-therapy drug used world...
-
Biological therapy in polymyalgia rheumatica Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Daniel Wendling
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of the elderly, treated mainly with systemic corticosteroids. The frequency of side effects of steroids is high in this aged popula...
-
The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Taner Coşkuner, Şengül Çağlayan, Özlem Akgün, Rüya Torun, Emine Nur Sunar Yayla, İ̇lknur Bagrul, Gülşah Kılbaş, Gülçin Otar Yener, Hülya Köse, Kübra Öztürk, Özge Baba, Mustafa Çakan, Ferhat Demir, Hafize Emine Sönmez, Mukaddes Kalyoncu, Sara Sebnem Kılıç, Selçuk Yüksel, Esra Bağlan, Sevcan A Bakkaloğlu, Erbil Ünsal, Nuray Aktay Ayaz, Betül Sözeri
To evaluate the safety of canakinumab using real-world data in patients with systemic juvenile idiopathic arthritis (sJIA) and autoinflammatory diseases (AID).This was a cross-sectional observation...
-
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency) Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Tro Sekayan, Dana H. Simmons, Annette von Drygalski
Congenital hemophilia B (HB) is an X-linked bleeding disorder resulting in Factor IX (FIX) deficiency and bleeding of variable severity. There is no cure for HB. Typical management consists of prop...
-
What role can LAG-3-blocking antibodies play in melanoma therapy? Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Piotr Rutkowski, Paulina Jagodzińska-Mucha
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 12, 2023)
-
Biological therapies for the treatment of psoriasis in pediatrics Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Mariam Nikolaishvili, Vito Di Lernia
Psoriasis is a multifactorial, immune-mediated condition with predominant skin involvement. It may develop at any age. In one-third of patients, the first symptoms of psoriasis start during childho...
-
What future do biological therapies have in the treatment of gout? Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Lisa K Stamp, Angelo Gaffo
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 12, 2023)
-
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients? Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Marta Loredo, Ignacio Braña, Rubén Queiro
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 12, 2023)
-
Antibody based therapeutics for autoimmune hemolytic anemia Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Francesca Cavallaro, Wilma Barcellini, Bruno Fattizzo
Autoimmune hemolytic anemia (AIHA) treatment has been revolutionized by the introduction of target therapies, mainly monoclonal antibodies (MoAbs).The anti-CD20 rituximab, which targets Ab producti...
-
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Xingchen Li, Peng Zhang, Hao Sun, Lijie Han, Zhongxing Jiang, Jifeng Yu
According to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentaf...
-
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Guro L Goll, Tore K Kvien
TNF inhibitors (TNFi) are in widespread use to treat a range of immune-mediated inflammatory diseases. However, the use of less expensive, biosimilar versions of these costly agents varies consider...
-
Bulevirtide and emerging drugs for the treatment of hepatitis D Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Helen Y Xu, Jamie O Yang, Phillip H Chen, Steven-Huy B Han
Hepatitis delta virus (HDV) causes acute and chronic liver disease that requires the co-infection of the Hepatitis B virus and can lead to significant morbidity and mortality. Bulevirtide is a rece...
-
Anacaulase-bcdb for the treatment of severe thermal burns Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Yaron Shoham, Yuval Krieger, Jeremy Goverman
Accurate burn depth assessment and early excision of burn eschar with maximal dermal preservation are key concepts in the optimal care of burn injury. Although excision with knife has long since be...
-
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-28 Jacopo Simonetti, Giacomo Sgalla, Luca Richeldi
The use of pirfenidone and nintedanib in treating Idiopathic Pulmonary Fibrosis (IPF) has shown significant slowing down of the progressive functional decline in these patients. In recent times, an...
-
Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Reyna KV Lim, Matthew Buschman, Alisher Khasanov, Arthur Ledesma, Jiang Chen, Thanhtruc Nguyen, Joanna Guo, Lingna Li, Jonathan Huang, Jin Niu, Lisa Kerwin, Rengang Wang, Yurong Guo, Tong Zhu, Gunnar Kaufmann, Yanliang Zhang, Heyou Zhou, Henry Ji, Yanwen Fu
Solid tumors are becoming prevalent affecting both old and young populations. Numerous solid tumors are associated with high cMET expression. The complexity of solid tumors combined with the highly...
-
Non-traditional approaches for control of antibiotic resistance Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Siddharth C Umarje, Sanjiban K Banerjee
The drying up of antibiotic pipeline has necessitated the development of alternative therapeutic strategies to control the problem of antimicrobial resistance (AMR) that is expected to kill 10-mill...
-
The endosomal-lysosomal system in ADC design and cancer therapy Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Jeffrey V. Leyton
This discourse delves into the intricate connections between the endosomal-lysosomal system and antibody-drug conjugates (ADCs), shedding light on an essential yet less understood dimension of targ...
-
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Tomohiro Fujii, Yutaka Matsuda
In the field of bioconjugates, the focus on antibody – drug conjugates (ADCs) with novel payloads beyond the traditional categories of potent cytotoxic agents is increasing. These innovative ADCs e...
-
Antibody drug conjugates for glioblastoma: current progress towards clinical use Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Hui K Gan, Sagun Parakh, Laura D Osellame, Lawrence Cher, Anthony Uccellini, Umbreen Hafeez, Siddharth Menon, Andrew M Scott
Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the expe...
-
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy? Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 John A Hartley
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 11, 2023)
-
Antibody-drug conjugates in oncology: insights into Current challenges Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Ahmad Z. Al Meslamani, Mohammad F. Bostanudin
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 11, 2023)
-
Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target? Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Lorenzo Guidi, Carmine Valenza, Dario Trapani, Giuseppe Curigliano
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 11, 2023)
-
Managing adverse events of sacituzumab govitecan Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-12-15 Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
The development of antibody-drug conjugates (ADCs) have revolutionized treatment for breast cancer. Sacituzumab govitecan (SG), a Trop2-targeted ADC, has demonstrated remarkable efficacy in triple-...
-
Oncolytic virotherapies for pediatric tumors Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-10-05 Evan G Gross, Mohammad A Hamo, Dagoberto Estevez-Ordonez, Nicholas MB Laskay, Travis J Atchley, James M Johnston, James M Markert
Many pediatric patients with malignant tumors continue to suffer poor outcomes. The current standard of care includes maximum safe surgical resection followed by chemotherapy and radiation which ma...
-
Preparing for the third decade of biosimilars Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-09-14 Ivo Abraham
Published in Expert Opinion on Biological Therapy (Vol. 23, No. 8, 2023)
-
Current and preclinical treatment options for Merkel cell carcinoma Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-09-10 Büke Celikdemir, Roland Houben, Thibault Kervarrec, Mahtab Samimi, David Schrama
Merkel cell carcinoma (MCC) is a rare, highly aggressive form of skin cancer with neuroendocrine features. The origin of this cancer is still unclear, but research in the last 15 years has demonstr...
-
The importance of predicting patient responses to monoclonal antibodies for Crohn’s disease Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-08-30 Nisha Ganesh, Stephen B Hanauer, Parambir S Dulai
Crohn’s disease (CD) is a chronic immune-mediated inflammatory bowel disease that results in relapsing and remitting symptoms but progressive transmural bowel damage leading to significant morbidit...
-
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-08-30 Diana Clavellina, Wayne Balkan, Joshua M Hare
Acute myocardial infarction (AMI) remains a leading cause of death in the United States. The limited capacity of cardiomyocytes to regenerate and the restricted contractility of scar tissue after A...
-
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives Expert Opin. Biol. Ther. (IF 4.6) Pub Date : 2023-08-25 Lingbo He, Chun Yang, Yini Wang
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with a dismal prognosis. The underlying causes of HLH are diverse. However, the overabundance of cytokines was shared by all...